Ligand-activated peroxisome proliferator-activated receptor β/δ modulates human endometrial cancer cell survival.
about
Fenretinide: a novel treatment for endometrial cancer.Expression profile of long non-coding RNAs is altered in endometrial cancer.The role of PPARγ-mediated signalling in skin biology and pathology: new targets and opportunities for clinical dermatology.Apoptotic effect of the selective PPARβ/δ agonist GW501516 in invasive bladder cancer cells.
P2860
Ligand-activated peroxisome proliferator-activated receptor β/δ modulates human endometrial cancer cell survival.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ligand-activated peroxisome pr ...... ometrial cancer cell survival.
@en
Ligand-activated peroxisome pr ...... ometrial cancer cell survival.
@nl
type
label
Ligand-activated peroxisome pr ...... ometrial cancer cell survival.
@en
Ligand-activated peroxisome pr ...... ometrial cancer cell survival.
@nl
prefLabel
Ligand-activated peroxisome pr ...... ometrial cancer cell survival.
@en
Ligand-activated peroxisome pr ...... ometrial cancer cell survival.
@nl
P2093
P2860
P1433
P1476
Ligand-activated peroxisome pr ...... ometrial cancer cell survival.
@en
P2093
D Chakravarti
D Monsivais
M E Pavone
P2860
P2888
P304
P356
10.1007/S12672-013-0157-7
P577
2013-08-14T00:00:00Z